Albrecht Stenzinger
German Cancer Research Center · 989 works · 30,162 citations · h-index 81
Top works
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival
- Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
- Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay
- Detection and Segmentation of Cell Nuclei in Virtual Microscopy Images: A Minimum-Model Approach
- Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas
- BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis
- Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors
- Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
- Sarcoma classification by DNA methylation profiling
- Classification of Cancer at Prostate MRI: Deep Learning versus Clinical PI-RADS Assessment
- Accurate and efficient detection of gene fusions from RNA sequencing data
- Interobserver variability in the application of the novel IASLC/ATS/ERS classification for pulmonary adenocarcinomas
- Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions
- The landscape of metastatic progression patterns across major human cancers
- Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers
- Integrative genomic and transcriptomic analysis of leiomyosarcoma
- Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)
- CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma